Home / David L. Joffe, BSPharm, CDE, FACA (page 5)

David L. Joffe, BSPharm, CDE, FACA

David L. Joffe, BSPharm, CDE, FACA
(Editor-in-Chief Diabetes In Control) A graduate of University of Kentucky College of Pharmacy, he has practiced in the Tampa Bay area since 1986, has been providing diabetes and cardiovascular care in Tampa Bay since 1995, and spent 2 years as an Eckerd Patient Care Pharmacist managing over 100 diabetes patients. Dave currently sees patients in over 30 primary care and endocrinologists offices.

Aug. 11, 2018

This week we have a couple of features that could have been for my wife. The first is a feature that shows the value of e-bikes and fitness, and the second is an item from our PharmD candidate Kennen Munoz Munoz on the addition of an SGLT-2 Inhibitor to insulin …

Read More »

Aug 9, 2018

Over the past couple of years we have seen the use of SGLT-2 Inhibitors increase and we now have 3 different molecules to choose from. There have been studies that show the cardiovascular benefits of the class as well as the benefit of combining them with GLP-1 analogs. This year …

Read More »

Aug. 9, 2018

Every time I look in the endocrinology journals and magazines, the last 4 or 5 pages are always chock full of employment opportunities for endocrinologists all over the country. Many of these ads are the same month after month, giving the indication of just how hard it is to find …

Read More »

August 4, 2018

Have you ever noticed that those of us born in the 50’s and 60’s tend to reminisce about how when we were kids, we had to walk or ride our bikes everywhere, and our parents always would make us play outside after school until dinner was served? We tend to …

Read More »

July 31, 2018

This week it is all about insulin, and for a good reason. Although we have some great oral and non-insulin injectables for the treatment of type 2 Diabetes, and many of these can be used with our type 1 patients, the fact remains that if you have type 1 diabetes …

Read More »

July 28, 2018

This week, it is all about devices, and how they look to change the way we manage diabetes. First off, we have a new device that seems to work similar to the V-Go insulin delivery system. This device becomes the 3rd “mechanical pump” that will be available to patients and, …

Read More »

July 24, 2018

Way back in 2002 we had an article on in our newsletter on the newly discovered INGAP peptide (http://www.diabetesincontrol.com/issue-111-item-19-ingap-peptide-an-initiator-of-beta-cell-growth/ ) This peptide was thought to be able to regenerate beta cells, and early on it looked like a possible cure. Over the past 16 years we have had multiple features on …

Read More »

July 21, 2018

Most announcements of new therapies for diabetes are made by branded drug companies and clinicians, and patients have learned about the “sticker shock” that is associated with these new medications. This week we have a feature that bucks the system, as new research on an old blood pressure medication shows …

Read More »

July 19, 2018

Many of our patients use basal insulin with few hypoglycemic problems. Even at large doses the risk of hypoglycemia is small in most of our type 2 insulin using patients. The problem comes when the patient is not adequately controlled and we decide to use mealtime insulin to get them …

Read More »

July 17, 2018

Over the years, the fasting glucose has been the standard testing point for diabetes control. However, we have always been proponents of 2-hour postprandial readings to help identify diabetes sooner. This is based on the concept of first phase insulin release, and how that prevents the rise of glucose levels …

Read More »